Denise Braendgaard: We are Now the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Denise Braendgaard, General Manager of Novo Nordisk Haemophilia Foundation, shared a post by Novo Nordisk Haemophilia & Haemoglobinopathies Foundation on LinkedIn:
”The day has finally arrived and I can’t hide my excitement: we are waking up to new horizons.
After years of preparation by our Council and Team – and inspired by our incredible partners – we are immensely proud to announce that we are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation.
It is much more than adding one word.
It represents hope for people affected by haemoglobinopathies – specifically sickle cell disease and thalassaemia – in low and middle income countries who will benefit from our programmes. At the same time, it reaffirms our unwavering commitment to haemophilia.
It is an expansion of our vision and scope, a bold declaration of our continued, long-term dedication after 20 years of Impacting Care. Together.”
Quoting Novo Nordisk Haemophilia & Haemoglobinopathies Foundation’s post:
”We are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation
Proudly, we are unveiling our Foundation’s new chapter:
We are expanding our support beyond people with haemophilia to people with sickle cell disease and thalassaemia as well.
Building on two decades of work in haemophilia, and enabled by a renewed partnership with the Novo Nordisk Foundation and the continued funding from our founder, Novo Nordisk, we are expanding our scope to include haemoglobinopathies. We will apply our proven, partnership-led model to develop tailored programmes that benefit people with haemophilia and haemoglobinopathies, their healthcare professionals, and families – always adapted to local needs.
Let us tell you more here.”

Keep up with Hemostasis Today.
-
Oct 25, 2026, 15:13Franky Biles: Celebrating Diversity and Driving Inclusion Through Representation
-
Oct 25, 2026, 14:47Siddharth Mittal: A Sheet-Like Effluent Deposit During Plasma Exchange in iTTP
-
Oct 25, 2026, 14:16Alejandro González Veliz: Can Factor XIa Inhibition Prevent Recurrent Ischemic Events Without Increasing Bleeding?
-
Oct 25, 2026, 13:0910 Posts Not to Miss This Week
-
Oct 25, 2026, 13:02Thomas Dayspring: Advancing Cardiovascular Risk Assessment Through Multidisciplinary Lipid Care
-
Oct 25, 2026, 12:46Ahmar U. Zaidi: RISE UP Study on Sickle Cell Disease
-
Oct 25, 2026, 10:32Jan Sloves: Advanced Venous Ultrasound Training in Poland
-
Oct 25, 2026, 10:20Jeff Sternlicht: Rethinking Cardiovascular Prevention Through Atherosclerosis Imaging
-
Oct 25, 2026, 10:12Dino Mehic: PhD Opportunity in Platelet Biology and Bleeding Disorders